Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Advances in therapy·2021
Same author

COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Multiple sclerosis and related disorders·2021
Same author

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2021
Same author

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Multiple sclerosis and related disorders·2021
Same author

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.

Journal of neuroimmunology·2021
Same author

Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective.

Multiple sclerosis and related disorders·2021
Same journal

Classifying Psychedelic-Related Complications.

Current topics in behavioral neurosciences·2026
Same journal

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.

Current topics in behavioral neurosciences·2026
Same journal

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Current topics in behavioral neurosciences·2025
Same journal

Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.

Current topics in behavioral neurosciences·2025
Same journal

Correction to: Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.

Current topics in behavioral neurosciences·2025
Same journal

Ontologically Challenging Psychedelic Experiences: Considerations for Managing Associated Distress.

Current topics in behavioral neurosciences·2025
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.5K

Developing Biomarkers for MS.

Sharmilee Gnanapavan1, Gavin Giovannoni2

  • 1Centre for Neuroscience and Trauma, Blizard Institute, Barts and The London School of Medicine and Dentistry, Blizard Building, 4 Newark Street, London, E1 2AT, UK. s.gnanapavan@qmul.ac.uk.

Current Topics in Behavioral Neurosciences
|December 16, 2014
PubMed
Summary
This summary is machine-generated.

Neurofilaments show promise as sensitive biomarkers for monitoring multiple sclerosis (MS) disease activity and disability. Their development as surrogate outcomes is crucial for accurate diagnosis and treatment monitoring in MS clinical trials.

Keywords:
BiobankBiomarkerNetworksNeurofilamentsQualificationValidation

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Related Experiment Videos

Last Updated: Apr 19, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.5K
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

4.6K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Area of Science:

  • Neuroscience and Clinical Neurology
  • Biomarker Development and Validation

Background:

  • Current multiple sclerosis (MS) clinical outcomes like relapse rates are insensitive to underlying pathology.
  • Measuring clinical disability in MS is challenging, often retrospective, and not suitable for clinical trial timeframes.
  • Biomarkers offer specificity for pathological processes, aiding in diagnosis, stratification, and monitoring of MS activity.

Purpose of the Study:

  • To discuss the development of neurofilaments as potential surrogate outcomes for disability in MS.
  • To highlight the critical importance of biomarker validation and qualification for scientific acceptance.
  • To address potential pitfalls in the biomarker development pathway for MS.

Main Methods:

  • Review and discussion of neurofilament development as MS biomarkers.
  • Exploration of validation and qualification processes for surrogate outcomes.
  • Analysis of challenges and pitfalls in biomarker research for MS.

Main Results:

  • Neurofilaments are proposed as specific indicators of pathological processes in MS.
  • Biomarkers, including neurofilaments, can monitor both overt and subclinical MS disease activity.
  • The development pathway emphasizes validation and qualification for clinical utility.

Conclusions:

  • Neurofilaments represent a promising avenue for objective MS disease activity and disability assessment.
  • Validated biomarkers are essential for advancing MS diagnosis, patient stratification, and treatment monitoring.
  • Careful consideration of development pitfalls is necessary for successful biomarker implementation in MS.